- Home
- GLMD vs APM Comparison
GLMD vs APM Comparison
Compare GLMD & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLMD
- APM
- Stock Information
- Founded
- GLMD 2000
- APM 2010
- Country
- GLMD Israel
- APM United Kingdom
- Employees
- GLMD N/A
- APM N/A
- Industry
- GLMD Biotechnology: Pharmaceutical Preparations
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- GLMD Health Care
- APM Health Care
- Exchange
- GLMD Nasdaq
- APM Nasdaq
- Market Cap
- GLMD 4.6M
- APM 4.1M
- IPO Year
- GLMD 2014
- APM 2018
- Fundamental
- Price
- GLMD $3.03
- APM $0.73
- Analyst Decision
- GLMD
- APM
- Analyst Count
- GLMD 0
- APM 0
- Target Price
- GLMD N/A
- APM N/A
- AVG Volume (30 Days)
- GLMD 47.4K
- APM 45.1K
- Earning Date
- GLMD 01-03-2025
- APM 01-03-2025
- Dividend Yield
- GLMD N/A
- APM N/A
- EPS Growth
- GLMD N/A
- APM N/A
- EPS
- GLMD N/A
- APM 0.00
- Revenue
- GLMD N/A
- APM N/A
- Revenue This Year
- GLMD N/A
- APM $157,729.10
- Revenue Next Year
- GLMD N/A
- APM N/A
- P/E Ratio
- GLMD N/A
- APM $208.83
- Revenue Growth
- GLMD N/A
- APM N/A
- 52 Week Low
- GLMD $2.56
- APM $0.46
- 52 Week High
- GLMD $23.80
- APM $17.49
- Technical
- Relative Strength Index (RSI)
- GLMD 49.41
- APM 39.21
- Support Level
- GLMD $2.81
- APM $0.67
- Resistance Level
- GLMD $3.35
- APM $0.77
- Average True Range (ATR)
- GLMD 0.27
- APM 0.08
- MACD
- GLMD 0.06
- APM 0.03
- Stochastic Oscillator
- GLMD 56.63
- APM 40.91
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.